

REMARKS

The Office Action mailed August 29, 2005 has been carefully considered. Applicants wish to thank the Examiner for the effort shown in evaluating this application.

Claims 1 through 10 are pending in this application; and Claims 1 through 9 have been indicated as being allowable. Claim 10 has been rejected under 35 U.S.C. §112, first paragraph.

Rejection under 35 U.S.C. § 112, first paragraph

Claim 10 has been rejected under 35 U.S.C. §112, first paragraph. In the Office Action mailed February 29, 2005 it was asserted that Claim 10 did not comply with the enablement requirement. While the Applicants do not necessarily agree with this assertion, in the interest of furthering prosecution and obtaining speedy allowance of this application, Claim 10 has been amended herewith to follow the kind suggestion of the Examiner. This suggestion was made in the telephonic interviews of July 21, 2005 and August 15, 2005, as memorialized in the Interview Summary which is of record for this application. That suggestion was "that a claim drawn to a treatment of asthma would be allowable".

Claim 10 has now been amended in accordance with that kind suggestion of the Examiner. It is believed that this overcomes the rejection, and it is requested that the rejection be withdrawn.

The undersigned practitioner believes that no new matter is introduced by the present amendment.


Conclusion:

In view of the foregoing discussion, it is believed that all 10 of the pending claims, as amended, fully comply with the legal requirements for allowance. Reconsideration and allowance of the application with pending claims are earnestly solicited.

If prosecution of this application can be expedited by a telephone conversation, the Examiner is invited to call the undersigned practitioner (collect if necessary) to discuss the application.

Enclosed herewith is a Petition under 37 C.F.R. § 1.136(a) to extend the time for response for three months, or until February 28, 2006. It is believed that no additional fees and charges are required at this time in connection with the application; however, if any fees or charges are required at this time, they may be charged to our Patent and Trademark Office Deposit Account No. 18-1982.

Respectfully submitted,


James W. Bolcsak, Reg. No.: 39,912
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone: (908) 231-5922
Telefax: (908) 231-2626